Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Neo-Bladder Construct for Overactive Bladder
NCT00594139Phase 2Withdrawn
- Sponsor
- Tengion, Inc.
- Start
- Jan 2008
- Primary completion
- Jan 2008
- Modality
- Device-based Delivery
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous neobladder construct in overactive bladder (OAB) and urge incontinence, sponsored by Tengion, Inc. Primary endpoints: Mean number of micturitions per day at 12 months and Overall safety at 12 months. Planned start Jan 2008; status: withdrawn.
02
Drugs
autologous neobladder construct
03
Conditions
overactive bladder (OAB)urge incontinence
Beyond the preview
Go deeper on NCT00594139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00594139.